Ericifolin: a novel antitumor compound from allspice that silences androgen receptor in prostate cancer

Carcinogenesis. 2013 Aug;34(8):1822-32. doi: 10.1093/carcin/bgt123. Epub 2013 Apr 8.

Abstract

Silencing of androgen receptor (AR) signaling is a specific and effective mechanism to cure cancer of the prostate (CaP). In this study, the isolation and characterization of a compound from the aromatic berries of Pimenta dioica (allspice) that silences AR is presented. Potential antitumor activities of an aqueous allspice extract (AAE) and a compound purified from the extract were tested on CaP cells. AAE inhibited tumor cell proliferation and colony formation (50% growth inhibition ∼40-85 µg/ml) but not the viability of quiescent normal fibroblasts or non-tumorigenic prostate cells. In tumor cells, AAE inhibited cell cycle progression at G1/S, induced apoptosis or autophagy. Apoptosis was by caspase-dependent poly (ADP ribose) polymerase cleavage. A caspase-independent, apoptosis-inducing factor-mediated mechanism of apoptosis caused cell death in castration-resistant AR-positive or AR-negative CaP cells, such as CWR22RV1, PC-3 or DU145 cells. Treatment with AAE decreased the levels of AR messenger RNA (mRNA), protein and silenced AR activity in AR-positive cells. AR depletion was due to inhibition of AR promoter activity and mRNA stability. Delayed tumor growth (~55%) without measurable systemic toxicity was observed in LNCaP tumor-bearing mice treated with AAE by oral or intraperitoneal routes. LNCaP tumor tissues from AAE-treated mice revealed increased apoptosis as a potential mechanism of antitumor activity of AAE. The chemical identity of bioactive compound in AAE was established through multistep high-performance liquid chromatography fractionation, mass and Nuclear Magnetic Resonance spectroscopies. The compound, eugenol 5-O-β-(6'-galloylglucopyranoside) or ericifolin (EF), showed antiproliferative, pro-apoptosis and anti-AR transcription activities. These results demonstrate a potential use of AAE and EF against prostate cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Apoptosis / genetics
  • Autophagy / drug effects
  • Autophagy / genetics
  • Caspases / genetics
  • Caspases / metabolism
  • Cell Cycle / drug effects
  • Cell Cycle / genetics
  • Cell Line
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Eugenol / analogs & derivatives*
  • Eugenol / pharmacology
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism
  • G1 Phase / drug effects
  • G1 Phase / genetics
  • Gene Silencing / drug effects*
  • Glycosides / pharmacology*
  • Humans
  • Male
  • Mice
  • Mice, Nude
  • Pimenta*
  • Poly(ADP-ribose) Polymerases / genetics
  • Poly(ADP-ribose) Polymerases / metabolism
  • Promoter Regions, Genetic / drug effects
  • Promoter Regions, Genetic / genetics
  • Prostatic Neoplasms, Castration-Resistant / genetics*
  • Prostatic Neoplasms, Castration-Resistant / metabolism
  • RNA, Messenger / genetics
  • Random Allocation
  • Receptors, Androgen / genetics*
  • Receptors, Androgen / metabolism*
  • S Phase / drug effects
  • S Phase / genetics
  • Transcription, Genetic / drug effects
  • Transcription, Genetic / genetics
  • Xenograft Model Antitumor Assays

Substances

  • AR protein, human
  • Antineoplastic Agents
  • Glycosides
  • RNA, Messenger
  • Receptors, Androgen
  • Eugenol
  • ericifolin
  • Poly(ADP-ribose) Polymerases
  • Caspases